Detalles de la búsqueda
1.
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.
Clin Infect Dis;
76(Suppl 2): S210-S214, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125468
2.
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a ß-Lactamase Inhibitor, in Healthy Subjects.
Antimicrob Agents Chemother;
64(7)2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32284380
3.
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
Antimicrob Agents Chemother;
64(3)2020 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31843995
4.
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
Antimicrob Agents Chemother;
63(9)2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307978
5.
Erratum for Lickliter et al., "Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a ß-Lactamase Inhibitor, in Healthy Subjects".
Antimicrob Agents Chemother;
67(6): e0047623, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154696
6.
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.
Antimicrob Agents Chemother;
62(11)2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30126953
7.
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Lancet Infect Dis;
23(9): 1072-1084, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37182534
8.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
N Engl J Med;
359(4): 339-54, 2008 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-18650512
9.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
N Engl J Med;
359(4): 355-65, 2008 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-18650513
10.
A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects.
Clin Transl Sci;
14(4): 1423-1430, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33934519
11.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clin Infect Dis;
50(4): 605-12, 2010 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20085491
12.
Effects of omeprazole on plasma levels of raltegravir.
Clin Infect Dis;
48(4): 489-92, 2009 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19143531
13.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet;
369(9569): 1261-1269, 2007 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-17434401
14.
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
AIDS;
17(16): 2345-9, 2003 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-14571186
15.
Ertapenem therapy for community-acquired pneumonia in the elderly.
J Am Geriatr Soc;
51(11): 1526-32, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14687380
16.
Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
Diagn Microbiol Infect Dis;
43(1): 61-4, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12052630
17.
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Clin Ther;
24(11): 1770-85, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12501873
18.
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Ann N Y Acad Sci;
1222: 83-9, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21434946
19.
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Lancet Infect Dis;
11(12): 907-15, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21933752
20.
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
J Acquir Immune Defic Syndr;
53(4): 456-63, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20306554